References
- Geller S, Myskowski PL, Pulitzer M, et al. Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature. Chin Clin Oncol. 2019;8(1):5–5. doi:10.21037/cco.2018.11.01
- Willemze R, Cerroni L, Kempf W, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 2019;133(16):1703–1714. doi:10.1182/blood-2018-11-881268
- American Cancer Society. Cancer Facts & Figures 2022. 2022.
- Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol. 2019;94(9):1027–1041. doi:10.1002/ajh.25577
- Wilson LD, Hinds GA, Yu JB. Age, race, sex, stage, and incidence of cutaneous lymphoma. Clin Lymphoma Myeloma Leuk. 2012;12(5):291–296. doi:10.1016/j.clml.2012.06.010
- Vaidya T, Baldri T. Mycosis Fungoides. 2022. In StatPearls, StatPearls Publishing. Accessed Nov 12, 2022.
- Denis D, Beneton N, Laribi K, et al. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res. 2019;11:2241–2251. doi:10.2147/CMAR.S138661
- Cerroni L. Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment. Semin Cutan Med Surg. 2018;37(1):2–10. doi:10.12788/j.sder.2018.002
- Pulitzer M, Myskowski PL, Horwitz SM, et al. Mycosis fungoides with large cell transformation: clinicopathological features and prognostic factors. Pathology. 2014;46(7):610–616. doi:10.1097/PAT.0000000000000166
- Wong HK, Mishra A, Hake T, et al. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155(2):150–166. doi:10.1111/j.1365-2141.2011.08852.x
- Micaily B, Miyamoto C, Kantor G, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998;42(2):361–364. doi:10.1016/s0360-3016(98)00218-1
- Hoppe RT, Fuks Z, Bagshaw MA. The rationale for curative radiotherapy in mycosis fungoides. Int J Radiat Oncol Biol Phys. 1977;2(9-10):843–851. doi:10.1016/0360-3016(77)90182-1
- Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1998;40(1):109–115. doi:10.1016/s0360-3016(97)00553-1
- Neelis KJ, Schimmel EC, Vermeer MH, et al. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–158. doi:10.1016/j.ijrobp.2008.06.1918
- Wang P, Gilbert M, Lim HW, et al. Single-fraction radiation therapy for localized cutaneous T-cell lymphoma. Pract Radiat Oncol. 2023;13(4):346–350. doi:10.1016/j.prro.2023.03.015
- Thomas TO, Agrawal P, Guitart J, et al. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747–753. doi:10.1016/j.ijrobp.2012.05.034
- Specht L, Dabaja B, Illidge T, et al. Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 2015;92(1):32–39. doi:10.1016/j.ijrobp.2015.01.008
- Patel AM, West L, Atluri PS, et al. Optimizing palliative focal radiation therapy dose in primary cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2020;108(3):S166–S167. doi:10.1016/j.ijrobp.2020.07.936
- Masters AH, Hughes RT, Strowd L, et al. Efficacy of low-dose radiotherapy for refractory mycosis fungoides of the face. JAAD Case Rep. 2019;5(4):348–351. doi:10.1016/j.jdcr.2019.01.027
- Desai M, Liu S, Parker S. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sezary syndrome in the southeastern United States: a single-institution cohort. J Am Acad Dermatol. 2015;72(2):276–285. doi:10.1016/j.jaad.2014.10.019